環戊丙酸雌二醇/醋酸甲羥孕酮
參考文獻

↑  IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer. . World Health Organization. 2007: 431. ISBN 9789283212911. （原始内容存档于2017-01-02） （英语）.
1 2 3 4 5 6 7  . www.drugs.com.   [2017-01-01]. （原始内容存档于2017-01-01）.
↑  . 健康醫療網. 2020-09-19  [2024-11-04].
1 2 3  World Health Organization. Stuart MC, Kouimtzi M, Hill SR , 编. . World Health Organization. 2009: 368–370. ISBN 9789241547659. hdl:10665/44053 .
↑  . Pharmacia & Upjohn Company LLC.   [2024-11-04].
↑  . www.drugs.com.   [2017-01-01]. （原始内容存档于2017-01-01）.
↑  . www.drugs.com.   [1 January 2017]. （原始内容存档于2017-01-01）.
1 2 3 4  Senanayake P, Potts M. .  Second. CRC Press. 2008: 51. ISBN 9780203347324. （原始内容存档于2017-01-02） （英语）.
↑  World Health Organization. . Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑  World Health Organization. . Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.
1 2  Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S.  (PDF). World J Pharm Pharm Sci. 2014, 3 (10): 364–392  [2018-08-02]. ISSN 2278-4357. （原始内容 (PDF)存档于2017-08-10）.
1 2 3 4 5 6 7 8 9  Newton JR, D'arcangues C, Hall PE. . Journal of Obstetrics and Gynaecology. 1994, 4 (Suppl 1): S1–34. PMID 12290848. doi:10.3109/01443619409027641.
↑  Sang GW. . Contraception. April 1994, 49 (4): 361–385. PMID 8013220. doi:10.1016/0010-7824(94)90033-7. The exact formulation and the size of the microcrystals is most important for duration of action. The smaller particles are more rapidly dissolved than larger ones and, hence, MPA appears more rapidly in the circulation, with more rapid elimination from the body. This is also true for the once-a-month formulation, Cyclofem. From our laboratory’s data, the distribution of particle size of Cyclofem is showed in Table 2. [...] TABLE 2. Distribution of particle size of crystalline steroids in Cyclofem (aqueous suspension). Size of particle (μm): ≤4: 0.3%. 5–6: 7.3%. 6–8: 16.7%. 8–10: 29.0%. 10–13: 29.7%. 13–16: 9.9%. 16–20: 0.5%. >20: 0.1%.
1 2  Kaunitz AM. . Obstetrics and Gynecology Clinics of North America. December 2000, 27 (4): 741–780. PMID 11091987. doi:10.1016/S0889-8545(05)70171-6.
1 2  Kaunitz AM. . Clinical Obstetrics and Gynecology. March 2001, 44 (1): 73–91. PMID 11219248. S2CID 30793138. doi:10.1097/00003081-200103000-00011 .
↑  Nadakavukaren A.  Seventh. Waveland Press. 2011-02-28: 63–. ISBN 978-1-4786-0976-6.
↑  Levitt JI. . Cambridge University Press. 2015-04-30: 230–231. ISBN 978-1-316-29840-4.
1 2 3 4 5 6 7 8 9  Hall PE. . International Journal of Gynaecology and Obstetrics. August 1998, 62 (Suppl 1): S43–S56. PMID 9806239. S2CID 2826689. doi:10.1016/S0020-7292(98)00090-3.
↑  Coutinho EM, Carlos de Souza J. . Journal of Reproduction and Fertility. March 1968, 15 (2): 209–214. PMID 5643482. S2CID 37979625. doi:10.1530/jrf.0.0150209.
↑  Oriowo MA, Landgren BM, Stenström B, Diczfalusy E. . Contraception. April 1980, 21 (4): 415–424. PMID 7389356. doi:10.1016/S0010-7824(80)80018-7.
↑  d'Arcangues C. . World Health Forum. 1993, 14 (4): 439–440. PMID 8185807.
↑  Nagrath Arun; Malhotra Narendra; Seth Shikha. . Jaypee Brothers Medical Publishers Pvt. Ltd. 15 December 2012: 416–. ISBN 978-93-5090-575-3.
↑  Koetsawang S. . Contraception. April 1994, 49 (4): 387–398. PMID 8013221. doi:10.1016/0010-7824(94)90034-5.
1 2  . drugs.com.
1 2  . drugs.com.
↑  Sweetman SC (编). .  36th. London: Pharmaceutical Press. 2009: 2082. ISBN 978-0-85369-840-1.
↑  .
↑  IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; International Agency for Research on Cancer.  (PDF). IARC. 1 January 1999: 65  [2018-09-17]. ISBN 978-92-832-1272-0. （原始内容 (PDF)存档于28 August 2021）.
↑  IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer. . World Health Organization. 2007: 431–. ISBN 978-92-832-1291-1.
↑  Klitsch M. . Family Planning Perspectives. 1995, 27 (6): 246–253. JSTOR 2136177. PMID 8666089. doi:10.2307/2136177.
|  论 编激素避孕（英语：）（G02B, G03A） |
| --- | --- |
雄激素:  仅男性： Testosterone undecanoate  Trestolone 
雌激素:  己烯雌酚  雌二醇  Estradiol benzoate  Estradiol cypionate  Estradiol enanthate  戊酸雌二醇  炔雌醇  美雌醇  Ormeloxifene 
孕激素:  第一代： Estranes: 炔孕酮  Etynodiol diacetate  Lynestrenol  炔诺酮  醋酸炔诺酮  Norethisterone enanthate  异炔诺酮  Quingestanol 第二代： Estranes: Norethisterone enanthate  诺孕烯酮; Gonanes: 左炔诺孕酮  Norelgestromin  Norgestrel 第三代： Gonanes: 去氧孕烯  依托孕烯  Gestodene  Norgestimate 第四代： Estranes: Dienogest; Norpregnanes: Demegestone  Nomegestrol acetate  Promegestone  Trimegestone; Spironolactone derivatives: Drospirenone 其他： Pregnanes: Chlormadinone acetate  醋酸环丙孕酮  Medrogestone  醋酸甲羥孕酮  Megestrol acetate; Miscellaneous: 美服培酮  Ulipristal acetate; Ungrouped: Algestone acetophenide  地屈孕酮  孕三烯酮  孕酮  Proligestone